EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages

  Weller, Michael ^a   van den Bent, Martin ^c   Hopkins, Kirsten ^d   Tonn, Jörg C ^e   Stupp, Roger ^b   Falini, Andrea ^f   Cohen Jonathan Moyal, Elizabeth ^g   Frappaz, Didier ^h   Henriksson, Roger ⁱ   Balana, Carmen ^j   Chinot, Olivier ^k   Ram, Zvi ^l   Reifenberger, Guido ^m,n   Soffietti, Riccardo ^o   Wick, Wolfgang ^p,q  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e UNIVERSITY OF MUNICH   (Germany)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g INSTITUT CLAUDIUS REGAUD   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k AIX MARSEILLE UNIVERSITY   (France)

^l TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ Translational Skin Cancer Research   (Germany)

^o Main Hospital and University   (Italy)

^p UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^q GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINOLEVULINIC ACID; ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BEVACIZUMAB; CARBAMAZEPINE; CARMUSTINE; CEDIRANIB; COUMARIN DERIVATIVE; ENZASTAURIN; ETIRACETAM; GABAPENTIN; HARKOSERIDE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LAMOTRIGINE; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; NITROSOUREA DERIVATIVE; OSMOTIC AGENT; PHENYTOIN; PROCARBAZINE; STEROID; TEMOZOLOMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; WARFARIN DERIVATIVE;

ADJUVANT THERAPY; ASTROCYTOMA; BRAIN STEM TUMOR; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REHABILITATION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; COORDINATION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPILEPSY; FLUID ATTENUATED INVERSION RECOVERY MAGNETIC RESONANCE IMAGING; FOLLOW UP; GENE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; GLIOMATOSIS CEREBRI; GLIOSIS; HUMAN; IDH1 GENE; IDH2 GENE; INTRACRANIAL HYPERTENSION; MAGNETIC RESONANCE ANGIOGRAPHY; MENTAL STRESS; META ANALYSIS (TOPIC); MGMT GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RADIATION DOSE FRACTIONATION; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOCIAL SUPPORT; SPINAL CORD CANCER; TUMOR BIOPSY; TUMOR GROWTH; VENA CAVA FILTER; AGED; BRAIN NEOPLASMS; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; MALE; MEDICAL SOCIETY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS;

EID: 84904902698     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70011-7     Document Type: Review

References (72)

1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system 2007, IARC, Lyon.
2. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013, 14:e370-e379.
3. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013, 126:443-451.
4. Laperriere N, Zuraw L, Cairncross G Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64:259-273. the Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group.
5. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978, 49:333-343.
6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
7. Stewart LA Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018. the Glioma Meta-analysis Trialists (GMT) Group.
8. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001, 19:509-518. Medical Research Council Brain Tumor Working Party.
9. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874-5880.
10. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013, 81:1515-1522.
11. Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999, 17:2762-2771. the Temodal Brain Tumor Group.
12. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010, 28:4601-4608.
13. Desjardins A, Reardon DA, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14:7068-7073.
14. Chamberlain MC, Johnston S Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 2009, 91:359-367.
15. Seystahl K, Wiestler B, Hundsberger T, et al. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2013, 69:95-101.
16. Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 2013, 49:3477-3485.
17. Arita H, Narita Y, Fukushima S, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013, 126:267-276.
18. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013, 31:337-343.
19. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006, 24:2707-2714. the Intergroup Radiation Therapy Oncology Group Trial 9402.
20. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006, 24:2715-2722.
21. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013, 31:344-350.
22. Chamberlain MC, Johnston S Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009, 115:1734-1743.
23. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 2009, 72:1601-1606.
24. Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg 2008, 108:642-648.
25. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010, 120:707-718.
26. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715. the NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society.
27. Vuorinen V, Hinkka S, Färkkilä M, Jääskeläinen J Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta Neurochir (Wien) 2003, 145:5-10.
28. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of GBM prolongs survival in the era of radiochemotherapy. Ann Oncol 2013, 24:3117-3123.
29. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401. the ALA-Glioma Study Group.
30. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62:564-576. the ALA-Glioma Study Group.
31. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527-1535. the Association of French-Speaking Neuro-Oncologists.
32. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004, 22:1583-1588.
33. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012, 13:916-926. the Nordic Clinical Brain Tumour Study Group (NCBTSG).
34. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5:79-88.
35. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006, 148:269-275. the Executive Committee of the Gliadel Study Group.
36. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 2008, 3. CD007294.
37. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, the National Cancer Institute of Canada Clinical Trials Groupthe National Cancer Institute of Canada Clinical Trials Group.
38. Hart MG, Garside R, Rogers G, Stein K, Grant R Temozolomide for high grade glioma. Cochrane Database Syst Rev 2013, 4. CD007415.
39. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
40. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466. the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, the National Cancer Institute of Canada Clinical Trials Groupthe National Cancer Institute of Canada Clinical Trials Group.
41. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013, 31:4085-4091.
42. Chinot O, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-722.
43. Gilbert MR, Dignam J, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014, 370:699-708.
44. Weller M, Yung WK Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro Oncol 2013, 15:971.
45. Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012, 14(suppl 4):iv100-iv108.
46. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:511-519.
47. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010, 28:3048-3053.
48. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010, 28:1168-1174.
49. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013, 31:3212-3218.
50. Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010, 28:2051-2057.
51. Norden AD, Lesser GJ, Drappatz J, et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013, 15:930-935.
52. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
53. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
54. Taal W, Oosterkamp HM, Walenkamp AME, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB study): a randomised controlled phase 2 trial. Lancet Oncol 2014, 15:943-953.
55. Herrlinger U, Felsberg J, Küker W, et al. Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 2002, 52:390-399.
56. Sanson M, Cartalat-Carel S, Taillibert S, et al. Initial chemotherapy in gliomatosis cerebri. Neurology 2004, 63:270-275. the ANOCEF group.
57. Glas M, Bähr O, Felsberg J, et al. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011, 70:445-453. the Neuro-Oncology Group of the German Cancer Society.
58. Rachinger W, Grau S, Holtmannspötter M, Herms J, Tonn JC, Kreth FW Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. J Neurol Neurosurg Psychiatry 2009, 80:1134-1139.
59. Laigle-Donadey F, Doz F, Delattre JY Brainstem tumors. Handb Clin Neurol 2012, 105:585-605.
60. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
61. Perry JR Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 2012, 14(suppl 4):iv73-iv80.
62. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010, 8:1959-1965.
63. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008, 2. CD004424.
64. Kerrigan S, Grant R Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev 2011, 8. CD008586.
65. Rudà R, Trevisan E, Soffietti R Epilepsy and brain tumors. Curr Opin Oncol 2010, 22:611-620.
66. Weller M, Stupp R, Wick W Epilepsy meets cancer: when, why, and what to do about it?. Lancet Oncol 2012, 13:e375-e382.
67. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011, 77:1156-1164.
68. Rooney A, Grant R Pharmacological treatment of depression in patients with a primary brain tumour. Cochrane Database Syst Rev 2010, 3. CD006932.
69. Henriksson R, Asklund T, Poulsen HS Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 2011, 104:639-646.
70. Piil K, Juhler M, Jakobsen J, et al. Controlled rehabilitative and supportive care intervention trials in patients with high-grade gliomas and their caregivers: a systematic review. BMJ Support Palliat Care 2014, published online June 2. 10.1136/bmjspcare-2013-000593.
71. Heese O, Vogeler E, Martens T, et al. End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro Oncol 2013, 15:1251-1256. the German Glioma Network.
72. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol 2004, 11:577-581. the Guideline Standards Subcommittee of the EFNS Scientific Committee.